# Table 1: Contraindications for Oral Anti-Obesity Medications (AOMs)

## Overview
This table categorizes contraindications as either **Absolute** (hard eliminate) or **Relative** (caution/requires medical clearance). All contraindications must be evaluated by a qualified healthcare provider.

---

## üö® SPECIAL POPULATIONS - UNIVERSAL EXCLUSIONS

### Current Pregnancy
**‚õî ABSOLUTE CONTRAINDICATION FOR ALL WEIGHT LOSS MEDICATIONS**

- **All anti-obesity medications are contraindicated during pregnancy**
- **Action Required:** Exclude ALL medications if patient is currently pregnant
- **Clinical Note:** Weight loss is not appropriate during pregnancy
- **Follow-up:** Repeat assessment postpartum (after pregnancy and breastfeeding period)

**Breastfeeding Note:** Most AOMs are also contraindicated during breastfeeding. Assess individually based on medication-specific guidelines.

---

## Table 1: Medication-Specific Contraindications

| # | Health Condition/Status | Affected Medications | Contraindication Type | Clinical Guidance |
|---|------------------------|---------------------|----------------------|-------------------|
| **1** | **Hypertension** | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia<br>‚Ä¢ Contrave<br>‚Ä¢ Bupropion | **RELATIVE** | ‚ö†Ô∏è **Caution if well-controlled**<br>- May prescribe if BP consistently <140/90<br>- Regular BP monitoring required<br>- Document control status |
| **2** | **Recurrent Kidney Stones** | ‚Ä¢ Qsymia<br>‚Ä¢ Topiramate | **ABSOLUTE** | ‚õî **Hard eliminate**<br>- Topiramate increases stone risk<br>- Do not prescribe |
| **3** | **Planning Pregnancy (within 3 months)** | ‚Ä¢ Qsymia<br>‚Ä¢ Topiramate | **ABSOLUTE** | ‚õî **Hard eliminate**<br>- Teratogenic risk<br>- Requires contraception if prescribed |
| **4** | **Currently Pregnant** | ‚Ä¢ ALL MEDICATIONS | **ABSOLUTE** | ‚õî **UNIVERSAL EXCLUSION**<br>- Exclude all weight loss medications<br>- Reassess postpartum |
| **5** | **Taking Tamoxifen** | ‚Ä¢ Contrave<br>‚Ä¢ Bupropion | **ABSOLUTE** | ‚õî **Hard eliminate**<br>- Significant drug interaction<br>- Reduces tamoxifen efficacy |
| **6** | **ADD/ADHD on Treatment** | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia | **RELATIVE** | ‚ö†Ô∏è **Requires clearance**<br>- Consult with prescribing psychiatrist<br>- Risk of overstimulation |
| **7** | **Glaucoma** | ‚Ä¢ Phentermine<br>‚Ä¢ Qsymia<br>‚Ä¢ Topiramate<br>‚Ä¢ Vyvanse | **RELATIVE** | ‚ö†Ô∏è **Requires ophthalmology clearance**<br>- Angle-closure glaucoma: ABSOLUTE contraindication<br>- Open-angle glaucoma: May use with monitoring |
| **8** | **Cardiovascular Disease**<br>(CAD, MI, CVA, Stroke, Heart Failure, PAD) | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia | **RELATIVE** | ‚ö†Ô∏è **Requires cardiology clearance**<br>- Recent events (<6 months): likely ABSOLUTE<br>- Stable disease: may consider with monitoring<br>- Document event history clearly for insurance |
| **9** | **Intracranial Hypertension** | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia | **ABSOLUTE** | ‚õî **Hard eliminate**<br>- Stimulants can worsen condition |
| **10** | **Psychiatric Disorders**<br>*General (Depression, Anxiety)* | ‚Ä¢ Contrave<br>‚Ä¢ Bupropion<br>‚Ä¢ Topiramate<br>‚Ä¢ Qsymia | **RELATIVE** | ‚ö†Ô∏è **Caution required**<br>- May use with psychiatric monitoring<br>- Screen for suicidal ideation<br>- Avoid if unstable |
| **10a** | **Bipolar Disorder** | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ All Stimulants | **RELATIVE** | üö® **EXTREME CAUTION - REQUIRES PSYCHIATRIC CLEARANCE**<br>- Risk of triggering mania/hypomania<br>- **MUST be cleared by patient's psychiatrist**<br>- Document psychiatric approval<br>- Ensure mood stabilizer compliance |
| **11** | **History of Eating Disorders**<br>(Anorexia, Bulimia) | ‚Ä¢ Contrave<br>‚Ä¢ Bupropion<br>‚Ä¢ Topiramate<br>‚Ä¢ Qsymia<br>‚Ä¢ Stimulants (case-by-case) | **RELATIVE** | ‚ö†Ô∏è **Extreme caution**<br>- Risk of relapse<br>- Requires mental health clearance<br>- Close monitoring essential |
| **12** | **History of Substance Abuse** | ‚Ä¢ Phentermine<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia | **RELATIVE** | ‚ö†Ô∏è **Caution required**<br>- Schedule II stimulants have abuse potential<br>- Assess recovery stability<br>- Consider non-stimulant alternatives |
| **13** | **Hyperthyroidism**<br>(Uncontrolled) | ‚Ä¢ Phentermine<br>‚Ä¢ Qsymia | **RELATIVE** | ‚ö†Ô∏è **Caution if controlled**<br>- ABSOLUTE if uncontrolled<br>- Stimulants worsen symptoms<br>- Check TSH levels |
| **14** | **Medullary Thyroid Cancer**<br>or Family History | ‚Ä¢ Wegovy (Semaglutide)<br>‚Ä¢ Zepbound (Tirzepatide) | **ABSOLUTE** | ‚õî **Hard eliminate - BLACK BOX WARNING**<br>- GLP-1 RAs contraindicated<br>- Risk of C-cell tumors |
| **15** | **Pancreatitis**<br>(History or Current) | ‚Ä¢ Wegovy<br>‚Ä¢ Zepbound | **RELATIVE to ABSOLUTE** | ‚ö†Ô∏è **Case-by-case assessment**<br>- Recent/acute: ABSOLUTE<br>- Remote history + normal lipase: RELATIVE<br>- Monitor lipase levels |
| **16** | **Gastroparesis** | ‚Ä¢ Wegovy<br>‚Ä¢ Zepbound | **RELATIVE** | ‚ö†Ô∏è **Caution - GI effects**<br>- GLP-1s delay gastric emptying<br>- May worsen symptoms<br>- Close monitoring required |
| **17** | **MAOI Use**<br>(Within 14 days) | ‚Ä¢ Phentermine<br>‚Ä¢ Bupropion<br>‚Ä¢ Contrave<br>‚Ä¢ Vyvanse<br>‚Ä¢ Qsymia | **ABSOLUTE** | ‚õî **Hard eliminate - DANGEROUS INTERACTION**<br>- Risk of hypertensive crisis<br>- 14-day washout required |
| **18** | **Concurrent GLP-1 or DM2 Medications** | ‚Ä¢ Wegovy<br>‚Ä¢ Zepbound | **ABSOLUTE** | ‚õî **Hard eliminate - DUPLICATION**<br>- Do not combine GLP-1 agonists<br>- Increased hypoglycemia risk<br>- Adjust diabetes medications |

---

## üìã Clinical Action Summary

### For ABSOLUTE Contraindications:
- **‚õî HARD ELIMINATE** the medication
- Do not prescribe under any circumstances
- Document reason for exclusion
- Offer alternative medications if available

### For RELATIVE Contraindications:
- **‚ö†Ô∏è FLAG FOR CAUTION** in screening results
- Require specialist clearance/approval where noted
- Document control status (controlled vs. uncontrolled)
- Obtain informed consent discussing risks
- Implement enhanced monitoring protocols
- Consider risk-benefit analysis

---

## üîÑ Reassessment Guidelines

### Pregnancy
- **Reassess postpartum:** After delivery and completion of breastfeeding
- Ensure patient is not planning immediate subsequent pregnancy
- Review updated health status

### Acute Conditions
- **Cardiovascular events:** Reassess 6-12 months post-event with cardiology clearance
- **Pancreatitis:** Reassess when acute episode resolved and lipase normalized

### Controlled Conditions
- **Hypertension, Hyperthyroidism, etc.:** Reassess when condition becomes well-controlled
- Document control parameters (BP readings, TSH levels, etc.)

---

## ‚öïÔ∏è Provider Responsibilities

1. **Thorough Medical History:** Obtain complete medical, psychiatric, and medication history
2. **Document Clearly:** Especially for insurance - specify cardiovascular event types (MI vs CVA vs PAD)
3. **Obtain Clearances:** Get written clearance from specialists when required (psychiatrist for bipolar, cardiologist for CV disease)
4. **Monitor Regularly:** Schedule appropriate follow-up based on patient risk factors
5. **Informed Consent:** Discuss risks, benefits, and alternatives with patient
6. **Drug Interactions:** Screen for all potential drug-drug interactions

---

## üè• Insurance Documentation Requirements

For insurance approval, clearly document:
- **Specific diagnoses** (not just "cardiovascular disease" but "MI 2022, stable CAD")
- **Control status** (e.g., "hypertension, well-controlled on lisinopril, BP 125/78")
- **Event dates** for cardiovascular history
- **Specialist clearances** obtained
- **Treatment trials** (lifestyle modifications attempted for ‚â•3 months)

---

## üìù Notes

1. This table provides general guidance and must be individualized to each patient
2. Always review current product labeling for the most up-to-date contraindication information
3. State regulations and insurance requirements may impose additional restrictions
4. When in doubt, consult with specialists and err on the side of patient safety
5. Document all clinical decision-making thoroughly

---

**Version:** 2.0
**Last Updated:** 2025-11-21
**Clinical Review:** Based on PA recommendations and current prescribing guidelines
